{"disease":{"id":"glaucoma-ocular-hypertension","name":"glaucoma ocular hypertension"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04967989","title":"Clarifying the Optimal Application of SLT Therapy Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":790,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT03691649","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":426,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT05181046","title":"Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Nanodropper, Inc.","has_results":false},{"nct_id":"NCT03691662","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":417,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT04133311","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":386,"lead_sponsor_name":"Santen SAS","has_results":true},{"nct_id":"NCT05495061","title":"A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"Santen Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03216902","title":"A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":241,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT03822559","title":"A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Santen Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05583474","title":"OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Otsuka Beijing Research Institute","has_results":false},{"nct_id":"NCT05503901","title":"A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Santen Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02822729","title":"A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Santen Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03697811","title":"DE-117 Spectrum 5 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT03858894","title":"Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT06689696","title":"24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring","phase":"","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Smartlens, Inc.","has_results":false},{"nct_id":"NCT06865144","title":"Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"East Coast Institute for Research","has_results":false},{"nct_id":"NCT07076303","title":"A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Brian Shafer","has_results":false},{"nct_id":"NCT03187418","title":"Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":true},{"nct_id":"NCT03927118","title":"Effect of Dexamethasone Implant on Optic Disc","phase":"","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Bulent Ecevit University","has_results":false},{"nct_id":"NCT03310580","title":"Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Aerie Pharmaceuticals","has_results":true},{"nct_id":"NCT02371746","title":"Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Envisia Therapeutics","has_results":true},{"nct_id":"NCT04061044","title":"A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":false},{"nct_id":"NCT05075226","title":"Visual Outcomes of Vivity in Patients With Well Controlled Glaucoma","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Maisonneuve-Rosemont Hospital","has_results":false},{"nct_id":"NCT02822742","title":"A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Santen Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03233308","title":"Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Aerie Pharmaceuticals","has_results":true}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}